Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 30, 2026 | $1.39 | +31.1% | $959.00M | +39.5% | $1.66 |
| Q1 FY26ended Mar 31, 2026 | May 5, 2026 | $1.91 | +2287.5% | $814.50M | +42.2% | $1.68 |
| Q4 FY25ended Dec 31, 2025 | — | $1.48 | +48.0% | $805.50M | +28.3% | — |
| Q3 FY25ended Sep 30, 2025 | — | $2.04 | +64.5% | $794.90M | +27.8% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.06 | +68.3% | $687.50M | +16.5% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.08 | −81.0% | $572.60M | +11.1% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.00 | −28.6% | $627.70M | +21.8% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.24 | +51.2% | $622.10M |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Neurocrine Biosciences shares, not any token. As of Jul 30, 2026, from Massive's standardised financials and the earnings calendar.
| +24.7% |
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.63 | — | $590.20M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.42 | — | $515.30M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.40 | — | $515.20M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.82 | — | $498.80M | — | — |